Neumora Therapeutics

#Neumora Therapeutics #Neuropsychiatric disorders #Neuroscience #Phase I trial #Schizophrenia #Vanderbilt University

Potentially game-changing schizophrenia drug enters trials

A potential schizophrenia treatment, discovered at Vanderbilt University in Tennessee in the US, has been cleared by the US Food and Drug Administration for use in Phase I clinical trials. NMRA-266, an allosteric modulator that works through a mechanism that has been clinically validated in the treatment of disorders like… Read More

#Editor's Choice #News #Regulatory